Emerging data suggest a partial regulatory role for FXR modulators in peripheral insulin sensitivity, suggesting a future role for FXR in the treatment of insulin resistance and T2DM [41–43]. This evidence concerns the gene NR1H4 and type 2 diabetes mellitus.